FDA-cleared profile

Rayvolve

AZmed · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Rayvolve supports clinicians by identifying suspected fractures, joint effusions, and dislocations on labeled radiographic views; it does not replace clinician interpretation.

Clinical role
Detection, localization, or diagnostic support
Images and patients
X-ray/Radiography · Musculoskeletal and chest/ribs radiographs across specified views
Key limitation
Keep in mind: The labeled claims depend on the specific anatomy and views; software output is adjunctive and original images remain available for interpretation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Rayvolve supports clinicians by identifying suspected fractures, joint effusions, and dislocations on labeled radiographic views; it does not replace clinician interpretation.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Musculoskeletal and chest/ribs radiographs across specified views Input: CR and DX radiographs received through a local-network DICOM node, limited to labeled anatomy/view combinations.
  • Who uses it?Intended users: Radiologists and emergency physicians.
  • What does the software produce?Output: A processed image with zone-based suspected findings or no-abnormality output; the original is neither modified nor deleted and is displayed first.
  • What is its most important limitation?Key limitation: The labeled claims depend on the specific anatomy and views; software output is adjunctive and original images remain available for interpretation.

Clinical takeaway. Clinical role: Rayvolve supports clinicians by identifying suspected fractures, joint effusions, and dislocations on labeled radiographic views; it does not replace clinician interpretation.

Evidence takeaway. Evidence from the reviewed source record: A standalone performance assessment used 6,246 radiographs for fractures, dislocations, and joint effusions; case-level sensitivity was 96.88%, specificity was 87.29%, and AUC was 97.47%. Two retrospective multi-reader, multi-case studies used 178 and 225 musculoskeletal radiographs with 20 readers; no clinical studies were conducted in support of the 510(k) submission.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Rayvolve supports clinicians by identifying suspected fractures, joint effusions, and dislocations on labeled radiographic views; it does not replace clinician interpretation.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Detection, localization, or diagnostic support
  • Exact FDA submission
  • Checked 2026-09-05
Required input
CR and DX radiographs received through a local-network DICOM node, limited to labeled anatomy/view combinations.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
A processed image with zone-based suspected findings or no-abnormality output; the original is neither modified nor deleted and is displayed first.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Adults and pediatric patients aged 2 years and older.
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Radiologists and emergency physicians.
  • Exact FDA submission
  • Checked 2026-09-19

The exact intended-use statement identifies radiologists and emergency physicians as the users.

Limitations
The labeled claims depend on the specific anatomy and views; software output is adjunctive and original images remain available for interpretation.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
A standalone performance assessment used 6,246 radiographs for fractures, dislocations, and joint effusions; case-level sensitivity was 96.88%, specificity was 87.29%, and AUC was 97.47%. Two retrospective multi-reader, multi-case studies used 178 and 225 musculoskeletal radiographs with 20 readers; no clinical studies were conducted in support of the 510(k) submission.
  • Exact FDA submission
  • Checked 2026-09-19

The exact FDA summary reports the standalone study, exact performance metrics, two MRMC studies, reader count, and the absence of clinical studies.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
A standalone performance assessment used 6,246 radiographs for fractures, dislocations, and joint effusions; case-level sensitivity was 96.88%, specificity was 87.29%, and AUC was 97.47%. Two retrospective multi-reader, multi-case studies used 178 and 225 musculoskeletal radiographs with 20 readers; no clinical studies were conducted in support of the 510(k) submission.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact FDA summary reports the standalone study, exact performance metrics, two MRMC studies, reader count, and the absence of clinical studies.

Reported sensitivity
96.88% (95% CI: 96.10%, 97.51%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
87.29% (95% CI: 86.21%, 88.30%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Artificial intelligence algorithm for fracture detection in pediatric radiographs

  • DesignRetrospective external validation
  • Population2,549 pediatric emergency-department trauma patients aged 0-17 years; 5,865 radiographs
  • Scopeproduct family
  • Tested versionRayvolve family; exact K260378 configuration not established
  • Samplen=2549
  • Sites1
  • IndependenceIndependence not established

PMID:34810137 · DOI:10.1016/j.diii.2021.10.007

The study includes patients younger than the K260378 labeled age and does not establish exact-release performance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: CR and DX radiographs received through a local-network DICOM node, limited to labeled anatomy/view combinations.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA 510(k) K260378: Rayvolve

  2. Routing

    Source context, not route validation: Connects to a local network using a DICOM node for CR/DX input and returns a processed image.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · FDA 510(k) K260378: Rayvolve

  3. AI processing

    Source context, not route validation: Cloud platform connected to the local network

    Scope: Exact FDA submission. Hosting region and security controls remain unverified.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · FDA 510(k) K260378: Rayvolve

  4. Returned objects

    Source context, not route validation: A processed image with zone-based suspected findings or no-abnormality output; the original is neither modified nor deleted and is displayed first.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA 510(k) K260378: Rayvolve

  5. Viewer/worklist/report

    Unresolved route: A processed image with zone-based suspected findings or no-abnormality output; the original is neither modified nor deleted and is displayed first.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA 510(k) K260378: Rayvolve

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Cloud platform connected to the local network
  • Exact FDA submission
  • Checked 2026-09-05

Hosting region and security controls remain unverified.

Integration
Connects to a local network using a DICOM node for CR/DX input and returns a processed image.
  • Exact FDA submission
  • Checked 2026-09-05

Family workflow context

AZmed describes Rayvolve as a fracture-detection AI tool integrated into its clinician console.

product family · checked 2026-09-05

This 2022 announcement is not proof of all 2026 functions, modalities, or integrations.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K260378
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Musculoskeletal and chest/ribs radiographs across specified views
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-05-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
27Fields reviewed
11Source classes checked
9Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

All stored metadata records were screened. PMID 34810137 is retained as contextual family evidence; remaining literature leads and NCT05187585 lacked exact K260378 configuration linkage or complete readable protocol/results, so no additional results were promoted. The current discovery snapshot contains 9 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision material, vendor product page, literature index, trial registry, fda device recall, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission

    No scoped public price or procurement award was reviewed.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "AZmed Rayvolve reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-06 - Exact FDA submission

    No dated, scoped security attestation was reviewed.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-06 - Exact FDA submission

    The FDA packet says user instructions are transmitted to each user; current onboarding/support terms were not established.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K260378: Rayvolve

    U.S. Food and Drug Administration - Published 2026-05-12 - Accessed 2026-09-19

    Scope: identity, clinicalUse, modality, anatomy, input, output, limitations, integration, deployment, evidenceSummary, purpose, intendedUsers

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rayvolve model card (K260378)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. AZmed's AI Tool Rayvolve Gains FDA Clearance for Fracture Detection

    AZmed - Published 2022-06-22 - Accessed 2026-09-05

    Scope: productFamilyWorkflow, implementationCapabilities

  8. Artificial intelligence algorithm for fracture detection in pediatric radiographs

    Diagnostic and Interventional Imaging; abstract via PubMed - Published 2021-11-19 - Accessed 2026-09-05

    Scope: contextualEvidenceStudy

Research history

  1. K260378 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253192

DeepXray Spina

Alpha Intelligence Manifolds, Inc.

Authorized purpose: Opportunistic review of frontal lumbar-spine or KUB radiographs in adults aged 50 years and older to flag possible low bone mineral density at L1-L4 for clinician follow-up; a negative result does not rule out low BMD.

Modality
X-ray/Radiography
Anatomy
Spine/Bone Health
Decision
2026-06-10
FDA-cleared K252953

Velmeni for Dentists (V4D) Endo-Perio

Velmeni, Inc.

Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.

Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Decision
2026-05-11
FDA-cleared K251934

qXR-Detect

Qure.Ai Technologies

Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.

Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Decision
2026-01-16
FDA-cleared K250914

MediAI-BA

Crescom Co., Ltd.

Authorized purpose: View and quantify bone age from 2D posteroanterior left-hand radiographs to aid pediatric radiologists assessing patients aged 2-18 years.

Modality
X-ray/Radiography
Anatomy
Left hand and wrist; skeletal maturity/bone age
Decision
2025-12-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history